|  |
| --- |
| **Number 115 – May 03, 2018** |

**MHDL Update**

Below are certain updates to the MassHealth Drug List (MHDL). See the MHDL for a complete listing of updates.

Additions

Effective May 7, 2018, the following newly marketed drugs have been added to the MHDL.

* Aliqopa (copanlisib) – **PA**
* benznidazole
* Endari (l-glutamine) – **PA**
* Fasenra (benralizumab) – **PA**
* Mepsevii (vestronidase alfa-vjbk) – **PA**
* Parsabiv (etelcalcetide) ^
* Qvar Redihaler (beclomethasone MDI, breath-actuated) – **PA**
* Solosec (secnidazole) – **PA**
* Sublocade (buprenorphine extended-release injection) – **PA**
* Symdeko (tezacaftor/ivacaftor) – **PA**

Updated MassHealth Brand Name Preferred Over Generic Drug List

Effective May 7, 2018, the following agents will be added to the MassHealth Brand Name Preferred Over Generic Drug List.

* Prevacid Solutab (lansoprazole orally disintegrating tablet) BP – **PA ≥ 2 years**
* Remodulin (treprostinil injection) BP – **PA**
* Zavesca (miglustat) BP – **PA**

**Legend**

**PA** Prior authorization is required. The prescriber must obtain prior authorization for the drug in order for the pharmacy to receive payment. Note: PA applies to both the brand-name and the FDA “A”-rated generic equivalent of listed product.

**BP**  Brand preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the nonpreferred drug generic equivalent.

**^** Available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.